Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Provocation test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    162 result(s) found for: Provocation test. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2018-000752-18 Sponsor Protocol Number: 17-924 Start Date*: 2019-02-19
    Sponsor Name:UMC Utrecht
    Full Title: Ajmaline provocation in asymptomatic PLN and PKP2 mutation carriers for early detection of Arrhythmogenic Cardiomyopathy
    Medical condition: Arrhythmogenic cardiomyopathie due to PLN or PKP2 mutations, asymptomatic family members who are carriers of PLN or PKp2 mutations, patients without structural heart disease who are referred for aj...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006447-95 Sponsor Protocol Number: CDX0159-07 Start Date*: 2022-09-09
    Sponsor Name:Celldex Therapeutics
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Inducible Urticaria
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004858 10012499 Dermatographic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004604-37 Sponsor Protocol Number: NL55891.078.15 Start Date*: 2017-02-17
    Sponsor Name:Erasmus University Medical Center
    Full Title: Aspirin provocation of patients with Systemic Mastocytosis
    Medical condition: Systemic mastocytosis is a myeloproliferative disorder in which there is an accumulation of aberrant mast cells. It has various subtypes, ranging from indolent to aggressive mastocytosis. Symptoms ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005079-21 Sponsor Protocol Number: LOTAB_2b_HDM Start Date*: 2018-08-23
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Alle...
    Medical condition: Patients Suffering from Mite-Induced Allergic Rhino-Conjunctivitis Without or With Controlled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002582-37 Sponsor Protocol Number: CS001/2005 Start Date*: 2006-01-13
    Sponsor Name:Allergie-Centrum-Charité Universitätsmedizin Berlin
    Full Title: Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients
    Medical condition: Urticaria is a very frequent skin condition characterised by transient wheal and flare type skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients are thought...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002663-11 Sponsor Protocol Number: PSD506-OAB-002 Start Date*: 2006-10-17
    Sponsor Name:Plethora Solutions Limited
    Full Title: An open-label, escalating dose, proof of concept study to determine the effects of single oral doses of PSD506 on unstable urinary bladder contractions induced by volume provocation in subjects wit...
    Medical condition: Unstable urinary bladder contractions induced by volume provocation in subjects with detrusor hyper-reflexia secondary to spinal injuries above T12.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002944-18 Sponsor Protocol Number: BIA-HDMP-201 Start Date*: 2016-11-14
    Sponsor Name:Bial Industrial Farmacéutica S.A.
    Full Title: MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC R...
    Medical condition: The disease under study is allergic rhinoconjunctivitis secondary to sensitization to DPT and DF. Included in the study are patients diagnosed with that disease who also have associated mild asthma...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004616-19 Sponsor Protocol Number: ABT-gpCPT001 Start Date*: 2018-09-12
    Sponsor Name:ASIT biotech S.A.
    Full Title: A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe grass pollen allergic...
    Medical condition: This clinical trial aims to evaluate a conjunctival provocation test (CPT) with the IMP gpCPT+ for the assessment and grading of grass pollen allergic rhinoconjunctivitis. Thus, a diagnostic solu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003018-11 Sponsor Protocol Number: CQGE031E12301 Start Date*: 2021-10-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolesce...
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10008675 Cholinergic urticaria LLT
    23.0 10040785 - Skin and subcutaneous tissue disorders 10012521 Dermographism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) SI (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005452-16 Sponsor Protocol Number: AL0705AV Start Date*: 2008-03-10
    Sponsor Name:Allergopharma Joachim Ganzer KG an afilliate of Merck KGaA, Darmstadt
    Full Title: A multicentre randomised placebo-controlled, double-blind clinical trial for eval¬ua¬tion of safety and efficacy of pre-seasonal specific immunotherapy with a hypoallergenic extract of a 6 grass an...
    Medical condition: IgE-mediated allergic diseases including symptoms of allergic rhinoconjunctivitis, controlled allergic bronchial asthma, triggered by grass/rye pollen allergens
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000597-29 Sponsor Protocol Number: 2017-02-CHRMT Start Date*: 2021-06-02
    Sponsor Name:Centre Hospitalier Régional Metz-Thionville
    Full Title: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
    Medical condition: mite allergenic rhinitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003543-67 Sponsor Protocol Number: 2007-285-31-3 Start Date*: 2007-10-30
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Assessment of bronchial hyperresponsiveness in children - inhalation of Mannitol compared to eucapnic voluntary hyperventilation and methacholine provocation
    Medical condition: Three different methods to assess airway hyperresponsiveness in children with allergic asthma will be compared.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004830-32 Sponsor Protocol Number: ICPCT-2011-UA-FF Start Date*: 2012-01-27
    Sponsor Name:FAES FARMA, S.A.
    Full Title: Effects of bilastine on nasal volume after allergen-induced rhinitis in patients with allergic rhinitis
    Medical condition: Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003756-33 Sponsor Protocol Number: EFC16720 Start Date*: 2021-03-25
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: A randomized, double-blind, placebo-controlled, multi-center, parallel-group study of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1-antihi...
    Medical condition: Cold Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000215-31 Sponsor Protocol Number: S65796 Start Date*: 2022-05-24
    Sponsor Name:UZ Leuven
    Full Title: A monocentric academic trial comparing the diagnostic value of history taking and nasal lysine aspirin provocation test in the diagnosis of AERD in CRSwNP patients
    Medical condition: Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic RhinoSinusitis with Nasal Polyps (CRSwNP)
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004855 10075084 Aspirin-exacerbated respiratory disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003063-34 Sponsor Protocol Number: GSDL_DE_17 Start Date*: 2017-12-11
    Sponsor Name:Lofarma S.p.A.
    Full Title: A double-blind, placebo-controlled dose-escalation study of carbamylated monomeric tree pollen drops in patients with a history of allergic rhinoconjunctivitis.
    Medical condition: Treatment of tree pollen-induced allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015739-34 Sponsor Protocol Number: FRA.GHAT.2009 Start Date*: 2009-12-09
    Sponsor Name:Goethe-Universität Frankfurt/Main
    Full Title: Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)
    Medical condition: This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children wi...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004889-18 Sponsor Protocol Number: 1.3 Start Date*: 2022-04-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab in patients with aspirin-exacerbated respiratory disease (AERD) -A single-center prospective pilot study
    Medical condition: Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad or Widal's triad, comprises the triad of allergic asthma, chronic rhinosinusitis with nasal polyps (CRswNP) and nonstero...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001822-89 Sponsor Protocol Number: SMART_1_2012 Start Date*: 2012-08-21
    Sponsor Name:Lofarma S.p.A.
    Full Title: A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002317-10 Sponsor Protocol Number: SC-31A Start Date*: 2019-04-17
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy
    Medical condition: Allergic rhinitis / rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 14:51:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA